1-15 of 143
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
CME/CETranslating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Aldosterone-Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease
CME/CEAldosterone-Targeted Therapies for Uncontrolled Hypertension in Chronic Kidney Disease
Jamie P. Dwyer, MD
J. Matthew Luther, MD, MSCI
Vivek Bhalla, MD
Continuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
CME/CEContinuing the Search: New Data on Hypercortisolism Prevalence in Difficult-to-Control Metabolic Conditions
Christian Mende, MD, FACP, FACN, FASN, FASH, FAHA
Deepak Bhatt, MD, MPH, MBA, FACC, FAHA
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
CME/CENavigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, PhD, FRCP
Claudia Seikrit, MD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
CME/CEVous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CETransforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD
- advertisement
Shifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidence-Based Therapies to Optimize Patient Outcomes
CME/CEShifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidence-Based Therapies to Optimize Patient Outcomes
Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Stephen J. Greene, MD, FACC, FHFSA
Anne Louise Peters, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Patient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes
CME/CEPatient Voices and Provider Partnerships to Advance Cardio-Kidney-Metabolic Outcomes
Jay B. Wish, MD
Richard Lafayette, MD, FACP
Dana Rizk, MD
Hong Zhang
Suzuki Yusuke, MD, PhD
The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
MinuteCE®The 4-Hit Hypothesis: Foundations of IgAN Pathogenesis
Richard Lafayette, MD, FACP
Dana Rizk, MD
Hong Zhang
- advertisement
Mechanism-Based Targeting: Why APRIL Matters in IgAN
MinuteCE®Mechanism-Based Targeting: Why APRIL Matters in IgAN
Suzuki Yusuke, MD, PhD
Dana Rizk, MD
Dana Rizk, MD
Suzuki Yusuke, MD, PhD
Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
MinuteCE®Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
Hong Zhang
